Immunotherapy plus kidney surgery for spread kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can sign consent to join this study before any study procedures
- You have metastatic kidney cancer confirmed under the microscope (clear cell, papillary, or chromophobe), possibly with sarcomatoid features
- You are well enough to be active most of the day (WHO performance status 0 to 1)
- Your doctors think you are a safe candidate for surgery based on a surgeon and anesthesia assessment
- Your cancer has not progressed at metastatic sites about 6 months after starting your first standard treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.